In this pilot study, we explored the possible synergism between IL-2 and gefitinib in terms of response rate, survival and toxicity, with the purpose of evaluating the efficacy of this association in advanced NSCLC. The gene discussed is IL2; the disease is non-small cell lung carcinoma.